Montelukast Sodium

Montelukast Sodium Manufacturers

• Cardinal Health
  

  ×

  Montelukast Sodium | Cardinal Health

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB)

  For prevention of EIB, a single dose of montelukast should be taken at least 2 hours before exercise. 
  
  The following doses are recommended:
  For adults and adolescents 15 years of age and older: one 10-mg tablet.
  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.  

  An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Camber Pharmaceuticals, Inc.
  

  ×

  Montelukast Sodium | Camber Pharmaceuticals, Inc.

  

  ---

  2.1 Asthma
  

  Montelukast sodium chewable tablets should be taken once daily in the evening. The following doses are recommended:
  For adults and adolescents 15 years of age and older: one 10-mg tablet.
  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.
  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.
  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.
  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-lnduced Bronchoconstriction (EIB)
  

  For prevention of EIB,a single dose of montelukast sodium chewable tablet should be taken at least 2 hours before exercise.
  The following doses are recommended:
  For adults and adolescents 15 years of age and older: one 10-mg tablet.
  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.
  An additional dose of montelukast sodium chewable tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium chewable tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist.Safety and efficacy in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium chewable tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium chewable tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.
  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:
  For adults and adolescents 15 years of age and older: one 10-mg tablet.
  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.
  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.
  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established. 
  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:
  For adults and adolescents 15 years of age and older: one 10-mg tablet.
  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.
  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.
  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium chewable tablets dose daily in the evening.

  Close
  No Recall

  More Info
• Proficient Rx Lp
  

  ×

  Montelukast Sodium | Unifirst First Aid Corporation

  

  ---

  spray over affected area if bandaged, let dry first not to be used on children under 12 years of age

  Close
  No Recall

  More Info
• American Health Packaging
  

  ×

  Montelukast Sodium | American Health Packaging

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established. 

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of  exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs. 

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet. 

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established. 

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Proficient Rx Lp
  

  ×

  Montelukast Sodium | Proficient Rx Lp

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

   For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• State Of Florida Doh Central Pharmacy
  

  ×

  Montelukast Sodium | State Of Florida Doh Central Pharmacy

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced bronchoconstriction (EIB)  is approved for Merck Sharp & Dohme Corp’s montelukast tablet products.  However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Ncs Healthcare Of Ky, Inc Dba Vangard Labs
  

  ×

  Montelukast Sodium | Ncs Healthcare Of Ky, Inc Dba Vangard Labs

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

   For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Proficient Rx Lp
  

  ×

  Montelukast Sodium | Proficient Rx Lp

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp's montelukast tablet products. However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Torrent Pharmaceuticals Limited
  

  ×

  Montelukast Sodium | Torrent Pharmaceuticals Limited

  

  ---

  2.1 Asthma

              Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one packet of       4-mg oral granules. 

              For pediatric patients 12 to 23 months of age: one packet of 4-mg oral granules.

              Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

              There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

         For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced bronchoconstriction (EIB)  is approved for Merck Sharp & Dohme Corp's montelukast tablet products.  However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information. 

  2.3 Allergic Rhinitis

              For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

              The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one packet of        4-mg oral granules.

              Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

              The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one packet of       4-mg oral granules.

              For pediatric patients 6 to 23 months of age: one packet of 4-mg oral granules.

              Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

              Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  2.5 Instructions for Administration of Oral Granules

              Montelukast sodium 4-mg oral granules can be administered either directly in the mouth, dissolved in 1 teaspoonful (5 mL) of cold or room temperature baby formula or breast milk, or mixed with a spoonful of cold or room temperature soft foods; based on stability studies, only applesauce, carrots, rice, or ice cream should be used. The packet should not be opened until ready to use. After opening the packet, the full dose (with or without mixing with baby formula, breast milk, or food) must be administered within 15 minutes. If mixed with baby formula, breast milk, or food, montelukast sodium oral granules must not be stored for future use. Discard any unused portion. Montelukast sodium oral granules are not intended to be dissolved in any liquid other than baby formula or breast milk for administration. However, liquids may be taken subsequent to administration. Montelukast sodium oral granules can be administered without regard to the time of meals.

  Close
  No Recall

  More Info
• Mylan Institutional Inc.
  

  ×

  Montelukast Sodium | Procter And Gamble Manufacturing Company

  

  ---

  apply to underarms only

  Close
  No Recall

  More Info
• Pd-rx Pharmaceuticals, Inc.
  

  ×

  Montelukast Sodium | Pd-rx Pharmaceuticals, Inc.

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Physicians Total Care, Inc.
  

  ×

  Montelukast Sodium | Physicians Total Care, Inc.

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

   For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Rebel Distributors Corp
  

  ×

  Montelukast Sodium | Rebel Distributors Corp

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp's montelukast tablet products. However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Medvantx, Inc.
  

  ×

  Montelukast Sodium | Medvantx, Inc.

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

   For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Pd-rx Pharmaceuticals, Inc.
  

  ×

  Montelukast Sodium | Pd-rx Pharmaceuticals, Inc.

  

  ---

  2.1 Asthma

              Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. 

              Safety and effectiveness in pediatric patients less than 2 years of age with asthma have not been established.

              There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

              For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

              Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp's montelukast tablet products. However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information. 

  2.3 Allergic Rhinitis

              For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

              The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

              Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

              The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. 

              Safety and effectiveness in pediatric patients younger than 2 years of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

              Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Roxane Laboratories, Inc.
  

  ×

  Montelukast Sodium | Roxane Laboratories, Inc.

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB)

  For prevention of EIB, a single 10 mg dose of montelukast sodium should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Gen-source Rx
  

  ×

  Montelukast Sodium | Gen-source Rx

  

  ---

  2.1 Asthma

  
  Montelukast sodium tablets should be taken once daily in the evening. The following dose is recommended:
   
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
   
  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.
   
  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older
  

  For prevention of EIB, a single 10 mg dose of montelukast sodium tablets should be taken at least 2 hours before exercise. An additional dose of montelukast sodium tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  
  
  

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is  not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  
  For allergic rhinitis, montelukast sodium tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.
   
  The following dose for the treatment of symptoms of seasonal allergic rhinitis is recommended:
   
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
   
  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.
   
  The following dose for the treatment of symptoms of perennial allergic rhinitis is recommended: 
   
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
   
  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  
  Patients with both asthma and allergic rhinitis should take only one montelukast sodium tablet dose daily in the evening.

  Close
  No Recall

  More Info
• Legacy Pharmaceutical Packaging
  

  ×

  Montelukast Sodium | Procter And Gamble Manufacturing Company

  

  ---

  apply to underarms only

  Close
  No Recall

  More Info
• Mylan Pharmaceuticals Inc.
  

  ×

  Montelukast Sodium | Bryant Ranch Prepack

  

  ---

  2.1 Initial Dosing

  Fentanyl transdermal system should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.

  Due to the risk of respiratory depression, fentanyl transdermal system is only indicated for use in patients who are already opioid-tolerant. Discontinue or taper all other extended-release opioids when beginning fentanyl transdermal system therapy. As fentanyl transdermal system is only for use in opioid-tolerant patients, do not begin any patient on fentanyl transdermal system as the first opioid.

  Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

  Initiate the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)]. Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy with fentanyl transdermal system when serum concentrations from the initial patch will peak [see Warnings and Precautions (5.2)].

  The recommended starting dose when converting from other opioids to fentanyl transdermal system is intended to minimize the potential for overdosing patients with the first dose.

  Discontinue all other around-the-clock opioid drugs when fentanyl transdermal system therapy is initiated.

  While there are useful tables of opioid equivalents readily available, there is substantial inter-patient variability in the relative potency of different opioid drugs and products. As such, it is preferable to underestimate a patient’s 24-hour fentanyl requirements and provide rescue medication (e.g., immediate-release opioid) than to overestimate the 24-hour fentanyl requirements which could result in adverse reactions. In a fentanyl transdermal system clinical trial, patients were converted from their prior opioid to fentanyl transdermal system using Table 1 as a guide for the initial fentanyl transdermal system dose.

  Consider the following when using the information in Table 1:

  This is not a table of equianalgesic doses. The conversion doses in this table are only for the conversion from one of the listed oral or parenteral opioid analgesics to fentanyl transdermal system. The table cannot be used to convert from fentanyl transdermal system to another opioid. Doing so will result in an overestimation of the dose of the new opioid and may result in fatal overdose.

  To convert patients from oral or parenteral opioids to fentanyl transdermal system, use Table 1. Do not use Table 1 to convert from fentanyl transdermal system to other therapies because this conversion to fentanyl transdermal system is conservative and will overestimate the dose of the new agent.

  Table 1*. Dose Conversion to Fentanyl Transdermal System

  Current Analgesic

  Daily Dosage (mg/day)

  Oral morphine

  60-134

  135-224

  225-314

  315-404

  Intramuscular or
  Intravenous morphine

  10-22

  23-37

  38-52

  53-67

  Oral oxycodone

  30-67

  67.5-112

  112.5-157

  157.5-202

  Oral codeine

  150-447

  Oral hydromorphone

  8-17

  17.1-28

  28.1-39

  39.1-51

  Intravenous hydromorphone

  1.5-3.4

  3.5-5.6

  5.7-7.9

  8-10

  Intramuscular meperidine

  75-165

  166-278

  279-390

  391-503

  Oral methadone

  20-44

  45-74

  75-104

  105-134

  Recommended Fentanyl Transdermal System Dose

  25 mcg/hour

  50 mcg/hour

  75 mcg/hour

  100 mcg/hour

  Alternatively, for adult and pediatric patients taking opioids or doses not listed in Table 1, use the conversion methodology outlined above with Table 2.

  * Table 1 should not be used to convert from fentanyl transdermal system to other therapies because this conversion to fentanyl transdermal system is conservative. Use of Table 1 for conversion to other analgesic therapies can overestimate the dose of the new agent. Overdosage of the new analgesic agent is possible [see Dosage and Administration (2.3)].

  Alternatively, for adult and pediatric patients taking opioids or doses not listed in Table 1, use the following methodology:

  1.    Calculate the previous 24-hour analgesic requirement.
  2.    Convert this amount to the equianalgesic oral morphine dose using a reliable reference.

  Refer to Table 2 for the range of 24-hour oral morphine doses that are recommended for conversion to each fentanyl transdermal system dose. Use this table to find the calculated 24-hour morphine dose and the corresponding fentanyl transdermal system dose. Initiate fentanyl transdermal system treatment using the recommended dose and titrate patients upwards (no more frequently than 3 days after the initial dose and every 6 days thereafter) until analgesic efficacy is attained.

  3.    Do not use Table 2 to convert from fentanyl transdermal system to other therapies because this conversion to fentanyl transdermal system is conservative and will overestimate the dose of the new agent.

  Table 2*. Recommended Initial Fentanyl Transdermal System Dose Based Upon Daily Oral Morphine Dose

  Oral 24-hour
  Morphine
  (mg/day)

  Fentanyl Transdermal System
  Dose
  (mcg/hour)

  60-134

  25

  135-224

  50

  225-314

  75

  315-404

  100

  405-494

  125

  495-584

  150

  585-674

  175

  675-764

  200

  765-854

  225

  855-944

  250

  945-1034

  275

  1035-1124

  300

  NOTE: In clinical trials, these ranges of daily oral morphine doses were used as a basis for conversion to fentanyl transdermal system.

  * Table 2 should not be used to convert from fentanyl transdermal system to other therapies because this conversion to           fentanyl transdermal system is conservative. Use of Table 2 for conversion to other analgesic therapies can overestimate the dose of the new agent. Overdosage of the new analgesic agent is possible [see Dosage and Administration (2.5)].

  For delivery rates in excess of 100 mcg/hour, multiple systems may be used.

  Hepatic Impairment

  Avoid the use of fentanyl transdermal system in patients with severe hepatic impairment. In patients with mild to moderate hepatic impairment, start with one half of the usual dosage of fentanyl transdermal system. Closely monitor for signs of sedation and respiratory depression, including at each dosage increase [see Warnings and Precautions (5.14), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

  Renal Impairment

  Avoid the use of fentanyl transdermal system in patients with severe renal impairment. In patients with mild to moderate renal impairment, start with one half of the usual dosage of fentanyl transdermal system. Closely monitor for signs of sedation and respiratory depression, including at each dosage increase [see Warnings and Precautions (5.15), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

  2.2 Titration and Maintenance of Therapy

  Individually titrate fentanyl transdermal system to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving fentanyl transdermal system to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During chronic therapy, periodically reassess the continued need for opioid analgesics.

  The dosing interval for fentanyl transdermal system is 72 hours. Do not increase the fentanyl transdermal system dose for the first time until at least 3 days after the initial application. Titrate the dose based on the daily dose of supplemental opioid analgesics required by the patient on the second or third day of the initial application.

  It may take up to 6 days for fentanyl levels to reach equilibrium on a new dose [see Clinical Pharmacology (12.3)]. Therefore, evaluate patients for further titration after no less than two 3-day applications before any further increase in dosage is made.

  Base dosage increments on the daily dosage of supplementary opioids, using the ratio of 45 mg/24 hours of oral morphine to a 12 mcg/hour increase in fentanyl transdermal system dose.

  If unacceptable opioid-related adverse reactions are observed, the subsequent doses may be reduced. Adjust the dose to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

  A small proportion of adult patients may not achieve adequate analgesia using a 72-hour dosing interval and may require systems to be applied at 48 hours rather than at 72 hours, only if adequate pain control cannot be achieved using a 72-hour regimen. An increase in the fentanyl transdermal system dose should be evaluated before changing dosing intervals in order to maintain patients on a 72-hour regimen.

  Dosing intervals less than every 72 hours were not studied in children and adolescents and are not recommended.

  2.3 Administration of Fentanyl Transdermal System

  Fentanyl transdermal systems are for transdermal use, only.

  Proper handling of fentanyl transdermal system is necessary in order to prevent serious adverse outcomes, including death, associated with accidental secondary exposure to fentanyl transdermal system [see Warnings and Precautions (5.3)].

  Application and Handling Instructions

  Patients should apply fentanyl transdermal system to intact, non-irritated, and non-irradiated skin on a flat surface such as the chest, back, flank, or upper arm. In young children and persons with cognitive impairment, adhesion should be monitored and the upper back is the preferred location to minimize the potential of inappropriate patch removal. Hair at the application site may be clipped (not shaved) prior to system application. If the site of fentanyl transdermal system application must be cleansed prior to application of the patch, do so with clear water. Do not use soaps, oils, lotions, alcohol, or any other agents that might irritate the skin or alter its characteristics. Allow the skin to dry completely prior to patch application. Patients should apply fentanyl transdermal system immediately upon removal from the sealed package. The patch must not be altered (e.g., cut) in any way prior to application. Fentanyl transdermal system should not be used if the pouch seal is broken or if the patch is cut or damaged. The transdermal system is pressed firmly in place with the palm of the hand for 30 seconds, making sure the contact is complete, especially around the edges. Each fentanyl transdermal system may be worn continuously for 72 hours. The next patch is applied to a different skin site after removal of the previous transdermal system. If problems with adhesion of the fentanyl transdermal system occur, the edges of the patch may be taped with first aid tape. If problems with adhesion persist, the patch may be overlayed with a transparent adhesive film dressing. If the patch falls off before 72 hours, dispose of it by folding in half and flushing down the toilet. A new patch may be applied to a different skin site.   Patients (or caregivers who apply fentanyl transdermal system) should wash their hands immediately with soap and water after applying fentanyl transdermal system. Contact with unwashed or unclothed application sites can result in secondary exposure to fentanyl transdermal system and should be avoided. Examples of accidental exposure include transfer of a fentanyl transdermal system from an adult’s body to a child while hugging, sharing the same bed as the patient, accidental sitting on a patch and possible accidental exposure of a caregiver’s skin to the medication in the patch while applying or removing the patch. Instruct patients, family members, and caregivers to keep patches in a secure location out of the reach of children and of others for whom fentanyl transdermal system was not prescribed.

  Avoidance of Heat

  Instruct patients to avoid exposing the fentanyl transdermal system application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, sunbathing, hot baths, saunas, hot tubs, and heated water beds, while wearing the system [see Warnings and Precautions (5. 11)].

  2.4 Disposal Instructions

  Failure to properly dispose of fentanyl transdermal system has resulted in accidental exposures and deaths [see Warnings and Precautions (5.3)].

  Patients should dispose of used patches immediately upon removal by folding the adhesive side of the patch to itself, then flushing down the toilet.

  Unused patches should be removed from their pouches, the protective liners removed, the patches folded so that the adhesive side of the patch adheres to itself, and immediately flushed down the toilet.

  Patients should dispose of any patches remaining from a prescription as soon as they are no longer needed.

  2.5 Discontinuation of Fentanyl Transdermal System

  Significant amounts of fentanyl continue to be absorbed from the skin for 24 hours or more after the patch is removed [see Clinical Pharmacology (12.3)].

  To convert patients to another opioid, remove fentanyl transdermal system and titrate the dose of the new analgesic based upon the patient’s report of pain until adequate analgesia has been attained. Upon system removal, 17 hours or more are required for a 50% decrease in serum fentanyl concentrations. Withdrawal symptoms are possible in some patients after conversion or dose adjustment [see Warnings and Precautions (5.17)].

  Do not use Tables 1 and 2 to convert from fentanyl transdermal system to other therapies to avoid overestimating the dose of the new agent resulting in overdose of the new analgesic and possibly death.

  When discontinuing fentanyl transdermal system and not converting to another opioid, use a gradual downward titration, such as halving the dose every 6 days, in order to reduce the possibility of withdrawal symptoms [see Warnings and Precautions (5.17)]. It is not known at what dose level fentanyl transdermal system may be discontinued without producing the signs and symptoms of opioid withdrawal.

  2.1 Initial Dosing

  Fentanyl transdermal system should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.

  Due to the risk of respiratory depression, fentanyl transdermal system is only indicated for use in patients who are already opioid-tolerant. Discontinue or taper all other extended-release opioids when beginning fentanyl transdermal system therapy. As fentanyl transdermal system is only for use in opioid-tolerant patients, do not begin any patient on fentanyl transdermal system as the first opioid.

  Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

  Initiate the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)]. Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy with fentanyl transdermal system when serum concentrations from the initial patch will peak [see Warnings and Precautions (5.2)].

  The recommended starting dose when converting from other opioids to fentanyl transdermal system is intended to minimize the potential for overdosing patients with the first dose.

  Discontinue all other around-the-clock opioid drugs when fentanyl transdermal system therapy is initiated.

  While there are useful tables of opioid equivalents readily available, there is substantial inter-patient variability in the relative potency of different opioid drugs and products. As such, it is preferable to underestimate a patient’s 24-hour fentanyl requirements and provide rescue medication (e.g., immediate-release opioid) than to overestimate the 24-hour fentanyl requirements which could result in adverse reactions. In a fentanyl transdermal system clinical trial, patients were converted from their prior opioid to fentanyl transdermal system using Table 1 as a guide for the initial fentanyl transdermal system dose.

  Consider the following when using the information in Table 1:

  This is not a table of equianalgesic doses. The conversion doses in this table are only for the conversion from one of the listed oral or parenteral opioid analgesics to fentanyl transdermal system. The table cannot be used to convert from fentanyl transdermal system to another opioid. Doing so will result in an overestimation of the dose of the new opioid and may result in fatal overdose.

  To convert patients from oral or parenteral opioids to fentanyl transdermal system, use Table 1. Do not use Table 1 to convert from fentanyl transdermal system to other therapies because this conversion to fentanyl transdermal system is conservative and will overestimate the dose of the new agent.

  Table 1*. Dose Conversion to Fentanyl Transdermal System

  Current Analgesic

  Daily Dosage (mg/day)

  Oral morphine

  60-134

  135-224

  225-314

  315-404

  Intramuscular or
  Intravenous morphine

  10-22

  23-37

  38-52

  53-67

  Oral oxycodone

  30-67

  67.5-112

  112.5-157

  157.5-202

  Oral codeine

  150-447

  Oral hydromorphone

  8-17

  17.1-28

  28.1-39

  39.1-51

  Intravenous hydromorphone

  1.5-3.4

  3.5-5.6

  5.7-7.9

  8-10

  Intramuscular meperidine

  75-165

  166-278

  279-390

  391-503

  Oral methadone

  20-44

  45-74

  75-104

  105-134

  Recommended Fentanyl Transdermal System Dose

  25 mcg/hour

  50 mcg/hour

  75 mcg/hour

  100 mcg/hour

  Alternatively, for adult and pediatric patients taking opioids or doses not listed in Table 1, use the conversion methodology outlined above with Table 2.

  * Table 1 should not be used to convert from fentanyl transdermal system to other therapies because this conversion to fentanyl transdermal system is conservative. Use of Table 1 for conversion to other analgesic therapies can overestimate the dose of the new agent. Overdosage of the new analgesic agent is possible [see Dosage and Administration (2.3)].

  Alternatively, for adult and pediatric patients taking opioids or doses not listed in Table 1, use the following methodology:

  1.    Calculate the previous 24-hour analgesic requirement.
  2.    Convert this amount to the equianalgesic oral morphine dose using a reliable reference.

  Refer to Table 2 for the range of 24-hour oral morphine doses that are recommended for conversion to each fentanyl transdermal system dose. Use this table to find the calculated 24-hour morphine dose and the corresponding fentanyl transdermal system dose. Initiate fentanyl transdermal system treatment using the recommended dose and titrate patients upwards (no more frequently than 3 days after the initial dose and every 6 days thereafter) until analgesic efficacy is attained.

  3.    Do not use Table 2 to convert from fentanyl transdermal system to other therapies because this conversion to fentanyl transdermal system is conservative and will overestimate the dose of the new agent.

  Table 2*. Recommended Initial Fentanyl Transdermal System Dose Based Upon Daily Oral Morphine Dose

  Oral 24-hour
  Morphine
  (mg/day)

  Fentanyl Transdermal System
  Dose
  (mcg/hour)

  60-134

  25

  135-224

  50

  225-314

  75

  315-404

  100

  405-494

  125

  495-584

  150

  585-674

  175

  675-764

  200

  765-854

  225

  855-944

  250

  945-1034

  275

  1035-1124

  300

  NOTE: In clinical trials, these ranges of daily oral morphine doses were used as a basis for conversion to fentanyl transdermal system.

  * Table 2 should not be used to convert from fentanyl transdermal system to other therapies because this conversion to           fentanyl transdermal system is conservative. Use of Table 2 for conversion to other analgesic therapies can overestimate the dose of the new agent. Overdosage of the new analgesic agent is possible [see Dosage and Administration (2.5)].

  For delivery rates in excess of 100 mcg/hour, multiple systems may be used.

  Hepatic Impairment

  Avoid the use of fentanyl transdermal system in patients with severe hepatic impairment. In patients with mild to moderate hepatic impairment, start with one half of the usual dosage of fentanyl transdermal system. Closely monitor for signs of sedation and respiratory depression, including at each dosage increase [see Warnings and Precautions (5.14), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

  Renal Impairment

  Avoid the use of fentanyl transdermal system in patients with severe renal impairment. In patients with mild to moderate renal impairment, start with one half of the usual dosage of fentanyl transdermal system. Closely monitor for signs of sedation and respiratory depression, including at each dosage increase [see Warnings and Precautions (5.15), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

  2.2 Titration and Maintenance of Therapy

  Individually titrate fentanyl transdermal system to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving fentanyl transdermal system to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During chronic therapy, periodically reassess the continued need for opioid analgesics.

  The dosing interval for fentanyl transdermal system is 72 hours. Do not increase the fentanyl transdermal system dose for the first time until at least 3 days after the initial application. Titrate the dose based on the daily dose of supplemental opioid analgesics required by the patient on the second or third day of the initial application.

  It may take up to 6 days for fentanyl levels to reach equilibrium on a new dose [see Clinical Pharmacology (12.3)]. Therefore, evaluate patients for further titration after no less than two 3-day applications before any further increase in dosage is made.

  Base dosage increments on the daily dosage of supplementary opioids, using the ratio of 45 mg/24 hours of oral morphine to a 12 mcg/hour increase in fentanyl transdermal system dose.

  If unacceptable opioid-related adverse reactions are observed, the subsequent doses may be reduced. Adjust the dose to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

  A small proportion of adult patients may not achieve adequate analgesia using a 72-hour dosing interval and may require systems to be applied at 48 hours rather than at 72 hours, only if adequate pain control cannot be achieved using a 72-hour regimen. An increase in the fentanyl transdermal system dose should be evaluated before changing dosing intervals in order to maintain patients on a 72-hour regimen.

  Dosing intervals less than every 72 hours were not studied in children and adolescents and are not recommended.

  2.3 Administration of Fentanyl Transdermal System

  Fentanyl transdermal systems are for transdermal use, only.

  Proper handling of fentanyl transdermal system is necessary in order to prevent serious adverse outcomes, including death, associated with accidental secondary exposure to fentanyl transdermal system [see Warnings and Precautions (5.3)].

  Application and Handling Instructions

  Patients should apply fentanyl transdermal system to intact, non-irritated, and non-irradiated skin on a flat surface such as the chest, back, flank, or upper arm. In young children and persons with cognitive impairment, adhesion should be monitored and the upper back is the preferred location to minimize the potential of inappropriate patch removal. Hair at the application site may be clipped (not shaved) prior to system application. If the site of fentanyl transdermal system application must be cleansed prior to application of the patch, do so with clear water. Do not use soaps, oils, lotions, alcohol, or any other agents that might irritate the skin or alter its characteristics. Allow the skin to dry completely prior to patch application. Patients should apply fentanyl transdermal system immediately upon removal from the sealed package. The patch must not be altered (e.g., cut) in any way prior to application. Fentanyl transdermal system should not be used if the pouch seal is broken or if the patch is cut or damaged. The transdermal system is pressed firmly in place with the palm of the hand for 30 seconds, making sure the contact is complete, especially around the edges. Each fentanyl transdermal system may be worn continuously for 72 hours. The next patch is applied to a different skin site after removal of the previous transdermal system. If problems with adhesion of the fentanyl transdermal system occur, the edges of the patch may be taped with first aid tape. If problems with adhesion persist, the patch may be overlayed with a transparent adhesive film dressing. If the patch falls off before 72 hours, dispose of it by folding in half and flushing down the toilet. A new patch may be applied to a different skin site.   Patients (or caregivers who apply fentanyl transdermal system) should wash their hands immediately with soap and water after applying fentanyl transdermal system. Contact with unwashed or unclothed application sites can result in secondary exposure to fentanyl transdermal system and should be avoided. Examples of accidental exposure include transfer of a fentanyl transdermal system from an adult’s body to a child while hugging, sharing the same bed as the patient, accidental sitting on a patch and possible accidental exposure of a caregiver’s skin to the medication in the patch while applying or removing the patch. Instruct patients, family members, and caregivers to keep patches in a secure location out of the reach of children and of others for whom fentanyl transdermal system was not prescribed.

  Avoidance of Heat

  Instruct patients to avoid exposing the fentanyl transdermal system application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, sunbathing, hot baths, saunas, hot tubs, and heated water beds, while wearing the system [see Warnings and Precautions (5. 11)].

  2.4 Disposal Instructions

  Failure to properly dispose of fentanyl transdermal system has resulted in accidental exposures and deaths [see Warnings and Precautions (5.3)].

  Patients should dispose of used patches immediately upon removal by folding the adhesive side of the patch to itself, then flushing down the toilet.

  Unused patches should be removed from their pouches, the protective liners removed, the patches folded so that the adhesive side of the patch adheres to itself, and immediately flushed down the toilet.

  Patients should dispose of any patches remaining from a prescription as soon as they are no longer needed.

  2.5 Discontinuation of Fentanyl Transdermal System

  Significant amounts of fentanyl continue to be absorbed from the skin for 24 hours or more after the patch is removed [see Clinical Pharmacology (12.3)].

  To convert patients to another opioid, remove fentanyl transdermal system and titrate the dose of the new analgesic based upon the patient’s report of pain until adequate analgesia has been attained. Upon system removal, 17 hours or more are required for a 50% decrease in serum fentanyl concentrations. Withdrawal symptoms are possible in some patients after conversion or dose adjustment [see Warnings and Precautions (5.17)].

  Do not use Tables 1 and 2 to convert from fentanyl transdermal system to other therapies to avoid overestimating the dose of the new agent resulting in overdose of the new analgesic and possibly death.

  When discontinuing fentanyl transdermal system and not converting to another opioid, use a gradual downward titration, such as halving the dose every 6 days, in order to reduce the possibility of withdrawal symptoms [see Warnings and Precautions (5.17)]. It is not known at what dose level fentanyl transdermal system may be discontinued without producing the signs and symptoms of opioid withdrawal.

  Close
  No Recall

  More Info
• Avkare, Inc.
  

  ×

  Montelukast Sodium | Purdue Pharma Lp

  

  ---

  2.1  Important Administration Instructions

  Intermezzo is to be taken in bed when a patient wakes in the middle of the night and has difficulty returning to sleep. Intermezzo should only be taken if the patient has at least 4 hours of bedtime remaining before the planned time of waking [see Warnings and Precautions (5.1)].

  Intermezzo should be placed under the tongue and allowed to disintegrate completely before swallowing. The tablet should not be swallowed whole. For optimal effect, Intermezzo should not be administered with or immediately after a meal. The tablet should be removed from the pouch just prior to dosing.

  2.2  Basic Dosing Information

  The recommended and maximum dose of Intermezzo is 1.75 mg for women and 3.5 mg for men, taken only once per night as needed if a middle-of-the-night awakening is followed by difficulty returning to sleep. The recommended doses for women and men are different because women clear zolpidem from the body at a lower rate than men[see Use in Specific Populations (8.6)].

  2.3  Use with CNS Depressants

  The recommended Intermezzo dose for men and women who are taking concomitant CNS depressants is 1.75 mg. Dose adjustment of concomitant CNS depressants may be necessary when co-administered with Intermezzo because of potentially additive effects. The use of Intermezzo with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended [see Warnings and Precautions (5.1)].

  2.4  Use in Geriatric Patients

  Geriatric patients may be especially sensitive to the effects of zolpidem. The recommended dose of Intermezzo in men and women over 65 years old is 1.75 mg, taken only once per night if needed [see Use in Specific Populations (8.5)].

  2.5  Use in Patients with Hepatic Impairment

  The recommended dose of Intermezzo in patients with hepatic impairment is 1.75 mg, taken only once per night if needed [see Clinical Pharmacology (12.3)].

  Close
  No Recall

  More Info
• Aurobindo Pharma Limited
  

  ×

  Montelukast Sodium | Rite Aid

  

  ---

  do not take more than directed
  (see overdose warning)

  adults and children 12 years and over

  take 2 caplets every 4 hours

  swallow whole – do not crush, chew, or dissolve

  do not take more than 10 caplets in 24 hours

  children under 12 years: ask a doctor

  Close
  No Recall

  More Info
• Aurobindo Pharma Limited
  

  ×

  Montelukast Sodium | Aurobindo Pharma Limited

  

  ---

  2.1 Asthma
  

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:
  
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.
  
  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-lnduced Bronchoconstriction (EIB)

  For prevention of EIB, a single dose of montelukast should be taken at least 2 hours before exercise. The following doses are recommended:
  
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  An additional dose of montelukast sodium should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  2.3 Allergic Rhinitis
  

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.
  
  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:
  
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.
  
  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:
  
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis
  

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Aidarex Pharmaceuticals Llc
  

  ×

  Montelukast Sodium | Aidarex Pharmaceuticals Llc

  

  ---

  2.1 Asthma

  Montelukast sodium tablets should be taken once daily in the evening. The following dose is recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast sodium tablets should be taken at least 2 hours before exercise. An additional dose of montelukast sodium tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following dose for the treatment of symptoms of seasonal allergic rhinitis is recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following dose for the treatment of symptoms of perennial allergic rhinitis is recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium tablet dose daily in the evening.

  Close
  No Recall

  More Info
• Dr.reddy’s Laboratories Limited
  

  ×

  Montelukast Sodium | Dr.reddy's Laboratories Limited

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB)

  For prevention of EIB, a single dose of montelukast sodium should be taken at least 2 hours before exercise.

  The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet

  An additional dose of montelukast sodium should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs. 

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet . 

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established. 

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet .

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Kremers Urban Pharmaceuticals Inc.
  

  ×

  Montelukast Sodium | Kremers Urban Pharmaceuticals Inc.

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB)

  For prevention of EIB, a single dose of montelukast should be taken at least 2 hours before exercise.

  The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already takingmontelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting ß-agonist. Safety and effectiveness in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB. 

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Glenmark Generics Inc., Usa
  

  ×

  Montelukast Sodium | Glenmark Generics Inc., Usa

  

  ---

  2.1 Asthma

  Montelukast sodium tablets should be taken once daily in the evening. The following dose is recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast sodium tablets should be taken at least 2 hours before exercise. An additional dose of montelukast sodium tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following dose for the treatment of symptoms of seasonal allergic rhinitis is recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following dose for the treatment of symptoms of perennial allergic rhinitis is recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium tablet dose daily in the evening.

  Close
  No Recall

  More Info
• American Health Packaging
  

  ×

  Montelukast Sodium | American Health Packaging

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established. 

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights; this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.  

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Qualitest Pharmaceuticals
  

  ×

  Montelukast Sodium | Qualitest Pharmaceuticals

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB)

  For prevention of EIB, a single dose of montelukast should be taken at least 2 hours before exercise. 
  
  The following doses are recommended:
  For adults and adolescents 15 years of age and older: one 10-mg tablet.
  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.  

  An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Teva Pharmaceuticals Usa Inc
  

  ×

  Montelukast Sodium | Teva Pharmaceuticals Usa Inc

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB)

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet

  An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Apotex Corp
  

  ×

  Montelukast Sodium | Sun Pharma Global Fze

  

  ---

  
  

  Finasteride tablets 5 mg may be administered with or without meals.

  2.1 Monotherapy
  

  The recommended dose of finasteride tablets 5 mg is one tablet (5 mg) taken once a day [see Clinical Studies (14.1)].

  2.2 Combination with Alpha-Blocker
  

  The recommended dose of finasteride tablets 5 mg is one tablet (5 mg) taken once a day in combination with the alpha-blocker doxazosin [see Clinical Studies (14.2)].

  Close
  No Recall

  More Info
• Greenstone Llc
  

  ×

  Montelukast Sodium | Greenstone Llc

  

  ---

  2.1 Asthma
  

  Montelukast sodium tablets should be taken once daily in the evening. The following dose is recommended:
  
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
  
  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.
  
  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-lnduced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast sodium tablets should be taken at least 2 hours before exercise. An additional dose of montelukast sodium tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB. 

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products.  However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 

  2.3 Allergic Rhinitis
  

  For allergic rhinitis, montelukast sodium tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.
  
  The following dose for the treatment of symptoms of seasonal allergic rhinitis is recommended:
  
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
  
  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.
  
  The following dose for the treatment of symptoms of perennial allergic rhinitis is recommended:
  
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
  
  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis
  

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium tablet dose daily in the evening.

  Close
  No Recall

  More Info
• Greenstone Llc
  

  ×

  Montelukast Sodium | Greenstone Llc

  

  ---

  2.1 Asthma
  

  Montelukast sodium chewable tablets should be taken once daily in the evening. The following doses are recommended:
  
  For adults and adolescents 15 years of age and older: 10 mg.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.
  
  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a 10 mg dose of montelukast sodium chewable tablets should be taken at least 2 hours before exercise. An additional dose of montelukast sodium chewable tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium chewable tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium chewable tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis
  

  For allergic rhinitis, montelukast sodium chewable tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.
  
  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:
  
  For adults and adolescents 15 years of age and older: 10 mg.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established. 
  
  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:
  
  For adults and adolescents 15 years of age and older: 10 mg.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet. 
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis
  

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Cardinal Health
  

  ×

  Montelukast Sodium | Cardinal Health

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established. 

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights; this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.  

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Legacy Pharmaceutical Packaging
  

  ×

  Montelukast Sodium | Legacy Pharmaceutical Packaging

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established. 

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise.
  The following doses are recommended:
  For adults and adolescents 15 years of age and older: one 10-mg tablet.
  An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights; this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.  

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Mylan Pharmaceuticals Inc.
  

  ×

  Montelukast Sodium | Mylan Pharmaceuticals Inc.

  

  ---

  2.1 Recommended Dosage Adults

  The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20 mg to 40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited. The divided regimen was more effective in controlling trough (pre-dosing) blood pressure than the same dose given as a once-daily regimen.

  Use with Diuretics in Adults

  The recommended starting dose of benazepril hydrochloride tablets in a patient on a diuretic is 5 mg once daily. If blood pressure is not controlled with benazepril hydrochloride tablets alone, a low dose of diuretic may be added.

  Pediatric Patients 6 Years of Age and Older

  The recommended starting dose for pediatric patients is 0.2 mg/kg once per day. Titrate as needed to 0.6 mg/kg once per day. Doses above 0.6 mg/kg (or in excess of 40 mg daily) have not been studied in pediatric patients.

  Benazepril hydrochloride tablets are not recommended in pediatric patients less than 6 years of age or in pediatric patients with GFR less than 30 mL/min/1.73m² [see Use in Specific Populations (8.4)].

  2.2 Dose Adjustment for Renal Impairment

  For adults with a GFR < 30 mL/min/1.73 m2 (serum creatinine > 3 mg/dL), the recommended initial dose is 5 mg benazepril hydrochloride tablets once daily. Dosage may be titrated upward until blood pressure is controlled or to a maximum total daily dose of 40 mg. Benazepril hydrochloride tablets can also worsen renal function [see Warnings and Precautions (5.3)].

  2.3 Preparation of Suspension (for 150 mL of a 2 mg/mL Suspension)

  Add 75 mL of Ora-Plus®* oral suspending vehicle to an amber polyethylene terephthalate (PET) bottle containing fifteen benazepril hydrochloride 20 mg tablets, and shake for at least two minutes. Allow the suspension to stand for a minimum of 1 hour. After the standing time, shake the suspension for a minimum of one additional minute. Add 75 mL of Ora-Sweet®* oral syrup vehicle to the bottle and shake the suspension to disperse the ingredients. The suspension should be refrigerated at 2° to 8°C (36° to 46°F) and can be stored for up to 30 days in the PET bottle with a child-resistant screw-cap closure. Shake the suspension before each use.

  *Ora-Plus® and Ora-Sweet® are registered trademarks of Paddock Laboratories, Inc. Ora Plus® contains carrageenan, citric acid, methylparaben, microcrystalline cellulose, carboxymethylcellulose sodium, potassium sorbate, simethicone, sodium phosphate monobasic, xanthan gum, and water. Ora-Sweet® contains citric acid, berry citrus flavorant, glycerin, methylparaben, potassium sorbate, sodium phosphate monobasic, sorbitol, sucrose, and water.

  Close
  No Recall

  More Info
• State Of Florida Doh Central Pharmacy
  

  ×

  Montelukast Sodium | State Of Florida Doh Central Pharmacy

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced bronchoconstriction (EIB)  is approved for Merck Sharp & Dohme Corp’s montelukast tablet products.  However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Accord Healthcare Inc.
  

  ×

  Montelukast Sodium | H E B

  

  ---

  adults and children 12 years and older  take 2 tablets every 4 to 6 hours; do not take more than 8 tablets in 24 hours children ages 6 to 12 years take 1 tablet every 4 to 6 hours; do not take more than 4 tablets in 24 hours children under 6 years do not use this product in children under 6 years of age

  Close
  No Recall

  More Info
• Aphena Pharma Solutions – Tennessee, Llc
  

  ×

  Montelukast Sodium | Aphena Pharma Solutions - Tennessee, Llc

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp's montelukast tablet products. However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Preferred Pharmaceuticals, Inc.
  

  ×

  Montelukast Sodium | Preferred Pharmaceuticals, Inc.

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced bronchoconstriction (EIB)  is approved for Merck Sharp & Dohme Corp’s montelukast tablet products.  However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Bryant Ranch Prepack
  

  ×

  Montelukast Sodium | Bryant Ranch Prepack

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established. 

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.  

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Torrent Pharmaceuticals Limited
  

  ×

  Montelukast Sodium | Torrent Pharmaceuticals Limited

  

  ---

  2.1 Asthma

              Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. 

              Safety and effectiveness in pediatric patients less than 2 years of age with asthma have not been established.

              There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

              For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

              Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp's montelukast tablet products. However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information. 

  2.3 Allergic Rhinitis

              For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

              The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

              Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

              The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. 

              Safety and effectiveness in pediatric patients younger than 2 years of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

              Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Major Pharmaceuticals
  

  ×

  Montelukast Sodium | Major Pharmaceuticals

  

  ---

  2.1 Asthma

              Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one packet of       4-mg oral granules. 

              For pediatric patients 12 to 23 months of age: one packet of 4-mg oral granules.

              Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

              There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

         For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced bronchoconstriction (EIB)  is approved for Merck Sharp & Dohme Corp's montelukast tablet products.  However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information. 

  2.3 Allergic Rhinitis

              For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

              The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one packet of        4-mg oral granules.

              Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

              The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one packet of       4-mg oral granules.

              For pediatric patients 6 to 23 months of age: one packet of 4-mg oral granules.

              Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

              Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  2.5 Instructions for Administration of Oral Granules

              Montelukast sodium 4-mg oral granules can be administered either directly in the mouth, dissolved in 1 teaspoonful (5 mL) of cold or room temperature baby formula or breast milk, or mixed with a spoonful of cold or room temperature soft foods; based on stability studies, only applesauce, carrots, rice, or ice cream should be used. The packet should not be opened until ready to use. After opening the packet, the full dose (with or without mixing with baby formula, breast milk, or food) must be administered within 15 minutes. If mixed with baby formula, breast milk, or food, montelukast sodium oral granules must not be stored for future use. Discard any unused portion. Montelukast sodium oral granules are not intended to be dissolved in any liquid other than baby formula or breast milk for administration. However, liquids may be taken subsequent to administration. Montelukast sodium oral granules can be administered without regard to the time of meals.

  Close
  No Recall

  More Info
• Readymeds
  

  ×

  Montelukast Sodium | Readymeds

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced bronchoconstriction (EIB)  is approved for Merck Sharp & Dohme Corp’s montelukast tablet products.  However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10‑mg tablet.

  For pediatric patients 6 to 14 years of age: one 5‑mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4‑mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Direct Rx
  

  ×

  Montelukast Sodium | Direct Rx

  

  ---

  2.1 Asthma

  Montelukast sodium tablets should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist.

  Safety and efficacy in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium tablet dose daily in the evening.

  Close
  No Recall

  More Info
• Bryant Ranch Prepack
  

  ×

  Montelukast Sodium | Bryant Ranch Prepack

  

  ---

  2.1 Asthma
  

  Montelukast sodium chewable tablets should be taken once daily in the evening. The following doses are recommended:
  
  For adults and adolescents 15 years of age and older: 10 mg.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.
  
  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-lnduced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a 10 mg dose of montelukast sodium chewable tablets should be taken at least 2 hours before exercise. An additional dose of montelukast sodium chewable tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium chewable tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium chewable tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis
  

  For allergic rhinitis, montelukast sodium chewable tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.
  
  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:
  
  For adults and adolescents 15 years of age and older: 10 mg.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.
  
  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:
  
  For adults and adolescents 15 years of age and older: 10 mg.
  
  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.
  
  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.
  
  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis
  

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Cardinal Health
  

  ×

  Montelukast Sodium | Mid Valley Pharmaceuticals Llc

  

  ---

  Do not take more than 6 doses in 24 hours.

  Adults and children 12 years of age and over  2 teaspoonfuls (10mL) every 4 hours Children 6 to under 12 years of age  1 teaspoonfuls (5mL) every 4 hours Children under 6 years of age  Consult a doctor

  Close
  No Recall

  More Info
• Carilion Materials Management
  

  ×

  Montelukast Sodium | Carilion Materials Management

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

   For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products. However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10 mg tablet.

  For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.

  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• State Of Florida Doh Central Pharmacy
  

  ×

  Montelukast Sodium | State Of Florida Doh Central Pharmacy

  

  ---

  2.1 Asthma

  
  Montelukast sodium tablets should be taken once daily in the evening. The following dose is recommended:
   
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
   
  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.
   
  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-lnduced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast sodium tablets should be taken at least 2 hours before exercise. An additional dose of montelukast sodium tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium tablets daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium tablets for the chronic treatment of asthma has not been established to prevent acute episodes of EIB. 

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp’s montelukast tablet products.  However, due to Merck Sharp & Dohme Corp’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 

  2.3 Allergic Rhinitis

  
  For allergic rhinitis, montelukast sodium tablets should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.
   
  The following dose for the treatment of symptoms of seasonal allergic rhinitis is recommended:
   
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
   
  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.
   
  The following dose for the treatment of symptoms of perennial allergic rhinitis is recommended:
   
  For adults and adolescents 15 years of age and older: one 10 mg tablet.
   
  Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  
  Patients with both asthma and allergic rhinitis should take only one montelukast sodium tablet dose daily in the evening.

  Close
  No Recall

  More Info
• Avpak
  

  ×

  Montelukast Sodium | Avpak

  

  ---

  2.1 Asthma

  Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

  Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

  There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

  For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

  Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp's montelukast tablet products. However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  2.3 Allergic Rhinitis

  For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

  The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet.

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

  The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

  For adults and adolescents 15 years of age and older: one 10-mg tablet

  For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet

  For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet

  Safety and effectiveness in pediatric patients younger than 2 years of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

  Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info
• Bluepoint Laboratories
  

  ×

  Montelukast Sodium | Taro Pharmaceuticals U.s.a., Inc.

  

  ---

  Apply a thin layer of clobetasol propionate cream (emollient) USP, 0.05% to the affected skin areas twice daily and rub in gently and completely. Wash hands after each application.

  Clobetasol propionate cream (emollient) USP, 0.05% is a super-high potency topical corticosteroid; therefore, treatment should be limited to 2 consecutive weeks, and amounts greater than 50 grams per week should not be used.

  In moderate to severe plaque-type psoriasis, clobetasol propionate cream (emollient) USP, 0.05% applied to 5% to 10% of body surface area can be used for up to 4 weeks. The total dosage should not exceed 50 grams per week. When dosing for more than 2 weeks, any additional benefits of extending treatment should be weighed against the risk of HPA suppression. Therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Treatment beyond 4 consecutive weeks is not recommended.

  Clobetasol propionate cream (emollient), USP 0.05% should not be used with occlusive dressings.

  Close
  No Recall

  More Info
• Proficient Rx Lp
  

  ×

  Montelukast Sodium | Proficient Rx Lp

  

  ---

  2.1 Asthma

              Montelukast sodium should be taken once daily in the evening. The following doses are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. 

              Safety and effectiveness in pediatric patients less than 2 years of age with asthma have not been established.

              There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion.

  2.2 Exercise-Induced Bronchoconstriction (EIB) in Patients 15 Years of Age and Older

              For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β‑agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

              Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp's montelukast tablet products. However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information. 

  2.3 Allergic Rhinitis

              For allergic rhinitis, montelukast sodium should be taken once daily. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.

              The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet.

              Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.

              The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

              For adults and adolescents 15 years of age and older: one 10-mg tablet.

              For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.

              For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet. 

              Safety and effectiveness in pediatric patients younger than 2 years of age with perennial allergic rhinitis have not been established.

  2.4 Asthma and Allergic Rhinitis

              Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.

  Close
  No Recall

  More Info